News and Trends 11 Jun 2020 AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal …sales milestones. The two companies will jointly develop and commercialize three of Genmab’s anti-cancer antibody drugs, which are currently in phase I trials. Genmab’s antibody drugs — which are able… June 11, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 18 May 2017 Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and… May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 Get Ready for One of the Biggest New Drug Approvals of the Year …such as those implicated in atopic dermatitis, asthma and allergies. The antibody represents the first drug targeting the IL-4/IL-13 pathways. The antibody is indicated for the treatment of moderate to… March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2023 Five biotech companies making a name for themselves in Vancouver …antibody therapy treatment for COVID-19, when, in 2021, bamlanivimab, used together with etesevimab, became the first monoclonal antibody medicine for COVID-19 to receive U.S. Food and Drug Administration (FDA) Emergency… June 30, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 Transcenta monoclonal antibody gets FDA clearance Transcenta Holding Limited says its TST004 humanized monoclonal antibody targeting MASP2, has received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is… October 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2018 Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold …cancer patients that is very hard to treat. A checkpoint inhibitor antibody In the Phase II trial, Innate’s checkpoint inhibitor antibody was part of a combination therapy. While… October 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2017 Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody …anti-TNF-α antibody launched by Samsung Bioepis, making it the first company with biosimilars of all blockbusters that that target TNF-α. The other two are Benepali, a biosimilar of Amgen and… August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 30 May 2024 Covalent biologics: a new class of drugs on the horizon …American company Enlaza Therapeutics’ undisclosed preclinical pipeline is mainly focused on antibody drug conjugates (ADCs). These drugs consist of an antibody that attaches to cancer cell targets, a chemotherapy drug… May 30, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2020 French Partnership Deploys AI for Antibody Drug Discovery …development — will help users identify a therapeutic target and select a candidate antibody that can enter production. OSE Immunotherapeutics hopes to deploy the partnership on fusion protein technology called… February 13, 2020 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6… June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Biotheus enters agreement with Hansoh Pharma for bispecific antibody …EGFR/MET bispecific antibody (also known as PM1080) in China, Hong Kong, Macao and Taiwan. Under the terms of the agreement, Hansoh will be granted by Biotheus the exclusive rights to… November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016 And the highest funding in Europe this year goes to… Antibody-Drug Conjugates! …(ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest funding round of the… October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email